The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: A placebo-controlled, single-blind study

BMC Nutrition

Volumn 4, Issue 1, 2018, Pages

  Buckley, Martin ^a   Lacey, Sean ^b   Doolan, Andrea ^c   Goodbody, Emily ^c   Seamans, Kelly ^c  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

^b Munster Technological University   (Ireland)

^c Atlantia Food Clinical Trials   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85087329491     PISSN: None     EISSN: 20550928     Source Type: Journal    
DOI: 10.1186/s40795-018-0257-4     Document Type: Article

References (26)

1. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of helicobacter pylori infection. Helicobacter. 2014;19(Suppl 1):1-5.
2. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449-90.
3. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30.
4. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr. 2007;137(3 Suppl 2):812S-8S.
5. Ruggiero P. Use of probiotics in the fight against helicobacter pylori. World J Gastrointest Pathophysiol. 2014;5(4):384-91.
6. Zhu XY, Liu F. Probiotics as an adjuvant treatment in helicobacter pylori eradication therapy. J Dig Dis. 2017;18(4):195-202.
7. Patel A, Shah N, Prajapati JB. Clinical application of probiotics in the treatment of helicobacter pylori infection - a brief review. J Microbiol Immunol Infect. 2014;47(5):429-37.
8. Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, et al. Effects of anti-helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathogenesis. 2017;109:156-61.
9. Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. Potential role of probiotics in the management of gastric ulcer. Exp Ther Med. 2016;12(1):3-17.
10. Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001;73(2 Suppl):444S-50S.
11. Cain AM, Karpa KD. Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med. 2011;17(1):72-9.
12. Dharmani P, De Simone C, Chadee K. The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor. PLoS One. 2013;8(3):e58671.
13. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by helicobacter pylori? Aliment Pharmacol Ther. 2006;23(8):1077-86.
14. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of helicobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105-10.
15. Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H, et al. Significant reduction in helicobacter pylori load in humans with non-viable lactobacillus reuteri DSM17648: a pilot study. Probiotics Antimicrob Proteins. 2015;7(2):91-100.
16. Mehling H, Busjahn A. Non-viable lactobacillus reuteri DSMZ 17648 (Pylopass) as a new approach to helicobacter pylori control in humans. Nutrients. 2013;5(8):3062-73.
17. Zagari RM, Pozzato P, Martuzzi C, Fuccio L, Martinelli G, Roda E, et al. 13C-urea breath test to assess helicobacter pylori bacterial load. Helicobacter. 2005;10(6):615-9.
18. Perri F, Clemente R, Pastore M, Quitadamo M, Festa V, Bisceglia M, et al. The 13C-urea breath test as a predictor of intragastric bacterial load and severity of helicobacter pylori gastritis. Scand J Clin Lab Invest. 1998;58(1):19-27.
19. Hilker E, Domschke W, Stoll R. 13C-urea breath test for detection of helicobacter pylori and its correlation with endoscopic and histologic findings. J Physiol Pharmacol. 1996;47(1):79-90.
20. Sasayama Y, Kawano S, Tsuji S, Fusamoto H, Kamada T, Fukui H, et al. Relationship between interleukin-8 levels and myeloperoxidase activity in human gastric mucosa. J Gastroenterol Hepatol. 1997;12(2):104-8.
21. Varbanova M, Malfertheiner P. Bacterial load and degree of gastric mucosal inflammation in helicobacter pylori infection. Dig Dis. 2011;29(6):592-9.
22. Goh KL, Parasakthi N, Peh SC, Wong NW, Lo YL, Puthucheary SD. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol. 1991;26(11):1123-31.
23. Miyake K, Tsukui T, Shinji Y, Shinoki K, Hiratsuka T, Nishigaki H, et al. Teprenone, but not H2-receptor blocker or sucralfate, suppresses corpus helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H. pylori-induced interleukin-8 in MKN28 gastric epithelial cell lines. Helicobacter. 2004;9(2):130-7.
24. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-53.
25. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroentero. 2015;21(14):4345-57.
26. Zhang SY, Guo JQ, Liu L. Treating bacteria with bacteria: the role of probiotics in the eradication of helicobacter pylori. Int J Clin Exp Med. 2017;10(3):4330-41.